Hantavirus pulmonary syndrome treated with inhaled nitric oxide
- 1 August 1998
- journal article
- case report
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 17 (8) , 749-752
- https://doi.org/10.1097/00006454-199808000-00018
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Nitric oxide improves transpulmonary vascular mechanics but does not change intrinsic right ventricular contractility in an acute respiratory distress syndrome model with permissive hypercapniaCritical Care Medicine, 1996
- Hantavirus Pulmonary Syndrome: The First 100 US CasesThe Journal of Infectious Diseases, 1996
- Hantavirus pulmonary syndromeThe Lancet, 1996
- In acute lung injury, inhaled nitric oxide improves ventilation-perfusion matching, pulmonary vascular mechanics, and transpulmonary vascular efficiencyThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Isolation of the Causative Agent of Hantavirus Pulmonary SyndromeThe American Journal of Tropical Medicine and Hygiene, 1994
- Hantavirus Pulmonary Syndrome: A Clinical Description of 17 Patients with a Newly Recognized DiseaseNew England Journal of Medicine, 1994
- Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.Circulation, 1991
- Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.Proceedings of the National Academy of Sciences, 1990
- Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proceedings of the National Academy of Sciences, 1987
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987